Previous Close | 39.49 |
Open | 39.98 |
Bid | 40.01 x 100 |
Ask | 40.14 x 100 |
Day's Range | 38.96 - 40.21 |
52 Week Range | 9.60 - 45.31 |
Volume | |
Avg. Volume | 807,003 |
Market Cap | 2.455B |
Beta (5Y Monthly) | 2.30 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.52 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.23 |
Subscribe to Yahoo Finance Plus to view Fair Value for KYMR
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degrad
Kymera Therapeutics Inc (NASDAQ:KYMR) CFO Bruce Jacobs has sold 3,934 shares of the company's stock on March 4, 2024, according to a recent SEC filing.
Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) shareholders will have a reason to smile today, with the analysts making...